Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine

• Status: Active, not recruiting
• Trial end date: 2021-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florida
• Collaborator: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Treatments: Calcineurin Inhibitors; Tacrolimus

Criteria

Inclusion Criteria:

• adults undergoing liver and/or kidney transplantation

Exclusion Criteria:

• transplant patients with contraindications to tacrolimus